A retrospective analysis of 30,000 female Medicare patients found that osteoporosis fractures resulted in $15,522 per person in medical expenses over three years. The study also highlighted the need for osteoporosis prevention and treatment to mitigate fracture-related costs.
A Phase III study found that high-dose tirofiban was non-inferior to abciximab in reducing ST-segment elevation in STEMI patients. Tirofiban also showed improved safety profiles with lower thrombocytopenia rates compared to abciximab.
A consensus statement by ADA and ACC recognizes NMR measurement of LDL particle number as a more accurate assessment of cardiometabolic risk. This method appears to be more closely associated with cardiovascular disease risk than traditional LDL and non-HDL cholesterol measures.